Want to join the conversation?
$AMGN said its neuroscience programs continue to advance. In its migraine collaboration with Novartis, the company received positive results from Erenumab or AMG 334, its CGRP receptor antibody in its Phase 2b chronic migraine study. These data will be presented at the European Headache and Migraine Trust International Congress in Sept. 2016.
$EXTR has been on an interesting uptrend, fundamentals kinda tricky but solid technical. Earnings 5th